Description
Neurocrine Biosciences’ $211 Million CRENESSITY Surge: The Next Big Growth Engine?
Neurocrine Biosciences, Inc. reported third quarter 2026 results marked by record net product sales exceeding $1.1 billion, reflecting over 40% year-over-year growth and a milestone in the company’s operational profitability. This performance was driven by the strengthened commercial portfolio comprising three first-in-class medicines: INGREZZA, CRENESSITY, and VYKAT XR. INGREZZA, targeting tardive dyskinesia, generated $801 million in sales, reflecting 17% year-over-year growth supported by volume increases and prescription growth, with full-year guidance raised to $2.9 billion to $2.925 billion despite a $20 million order-timing benefit expected to reverse in Q4. The company anticipates continued double-digit volume growth against pricing pressures in 2027. CRENESSITY achieved quarterly sales of $211 million, supported by steady patient additions, strong persistency, and favorable reimbursement, now reaching more than 15% of the estimated diagnosed classic congenital adrenal hyperplasia population in the U.S. This reflects ongoing adoption primarily in pediatric endocrinology and increasing penetration in adult endocrinology.



